Who is the CEO of Oxurion NV?

The CEO of Oxurion NV is Thomas Graney.

What industry does Oxurion NV belong to?

Oxurion NV operates in the Biotechnology industry within the Healthcare sector.

Where is Oxurion NV headquartered?

Oxurion NV is headquartered at Gaston Geenslaan 1, Leuven, 3001, BE.

What is the IPO date of Oxurion NV?

Oxurion NV went public on January 17, 2007.

How many employees does Oxurion NV have?

Oxurion NV has approximately 27 full-time employees.

Oxurion NV

TBGNF•PNK

Healthcare

Biotechnology

$0.17

$0.00(0.00%)

Oxurion NV (TBGNF) Company Profile & Overview

Explore Oxurion NV’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Oxurion NV (TBGNF) Company Profile & Overview

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

SectorHealthcare

IndustryBiotechnology

CEOThomas Graney

Contact Information

https://www.oxurion.com

32 1 675 13 10

Gaston Geenslaan 1, Leuven, 3001

Company Facts

27 Employees

IPO DateJan 17, 2007

CountryBE

Frequently Asked Questions

;